Stockscreener 앱 받기
0.75
0.17%
-0.0013
시간 외 거래:
.76
0.01
+1.33%
전일 마감가:
$0.7513
열려 있는:
$0.75
하루 거래량:
251.63K
Relative Volume:
0.23
시가총액:
$1.60M
수익:
$4.70M
순이익/손실:
$-4.99M
주가수익비율:
-0.1168
EPS:
-6.42
순현금흐름:
$-5.29M
1주 성능:
+21.99%
1개월 성능:
-29.25%
6개월 성능:
-70.93%
1년 성능:
-78.57%
1일 변동 폭
$0.7117
$0.78
1주일 범위
$0.62
$0.78
52주 변동 폭
$0.4519
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
명칭
Salarius Pharmaceuticals Inc
전화
346-772-0346
주소
2450 HOLCOMBE BLVD, HOUSTON
SLRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.75 | 1.60M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-04-27 | 개시 | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc 주식(SLRX)의 최신 뉴스
What analysts say about Salarius Pharmaceuticals Inc. stockExceptional earning trajectories - PrintWeekIndia
Is Salarius Pharmaceuticals Inc. a good long term investmentRapid market gains - PrintWeekIndia
What drives Salarius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Salarius Pharmaceuticals Inc. Stock Analysis and ForecastRobust financial gains - jammulinksnews.com
Salarius Pharmaceuticals Modifies Security Holders’ Rights - TipRanks
Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com Australia
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World
How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser
Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - The Globe and Mail
Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN
Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener
Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard - The Manila Times
SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan
Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire
Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan
Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire
Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire
Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan
Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics. - AInvest
Salarius Pharmaceuticals Inc (SLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):